DISCUSSION Pruritus severely impacts quality of life in patients with CTCL (4). Treatment of
CTCL-associated pruritus remains challenging. By blocking the Th2 key cytokines IL4 and …

The initial improvement may be from the transient blockage of T-helper 2 inflammation with
shifting to a T-helper 1 tumor-suppressive effect via secretion of interferon-; however, the …

We present a 60‐year‐old man who was started on dupilumab for severe atopic dermatitis.
After initial improvement his skin deteriorated and 'unmasked'cutaneous T cell lymphoma …

DISCUSSION To achieve a targeted efficacy profile in patients with AD, biologic treatments
are projected to replace topical corticosteroids and systemic immunosuppressants. Since …

132 I CUTIS® WWW. MDEDGE. COM/DERMATOLOGY narrowband UVB was discontinued
completely. A comparison of the patient's flow cytometry analysis from before treatment to 3 …

In recent years, studies have associated dupilumab with unmasking or progression of
cutaneous T‐cell lymphoma (CTCL). The objective of this study was to synthesize reported …

At approximately the same time as dupilumab was initiated, he was started on 60 mg daily of
prednisone by his pulmonologist because of a history of restrictive lung disease of unknown …

Background Sézary syndrome is a leukaemic variant of cutaneous T‐cell lymphoma with
poor prognosis. With the exception of stem cell transplantation, current treatments for SS are …

Recent advances in the treatment of moderate-to-severe atopic dermatitis have led to
increased use of dupilumab, which is a human monoclonal antibody that binds to the …

Introduction: Dupilumab, the first biologic drug to be approved for the treatment of moderate
to severe atopic dermatitis in adolescents and adults, has shown efficacy and safety in …